Handok - Asset Resilience Ratio
Handok (002390) has an Asset Resilience Ratio of 0.38% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Handok to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Handok's Asset Resilience Ratio has changed over time. See 002390 equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Handok's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Handok.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩3.00 Billion | 0.38% |
| Total Liquid Assets | ₩3.00 Billion | 0.38% |
Asset Resilience Insights
- Limited Liquidity: Handok maintains only 0.38% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Handok Industry Peers by Asset Resilience Ratio
Compare Handok's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Huadong Medicine Co Ltd
SHE:000963 |
Drug Manufacturers - Specialty & Generic | 0.05% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Handok (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Handok.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.38% | ₩3.00 Billion ≈ $2.03 Million |
₩790.75 Billion ≈ $535.88 Million |
0.00pp |
| 2024-12-31 | 0.38% | ₩3.00 Billion ≈ $2.03 Million |
₩788.56 Billion ≈ $534.39 Million |
-0.06pp |
| 2023-12-31 | 0.44% | ₩3.50 Billion ≈ $2.37 Million |
₩790.34 Billion ≈ $535.60 Million |
+0.10pp |
| 2022-12-31 | 0.34% | ₩3.00 Billion ≈ $2.03 Million |
₩871.11 Billion ≈ $590.34 Million |
-0.25pp |
| 2021-12-31 | 0.59% | ₩5.00 Billion ≈ $3.39 Million |
₩841.56 Billion ≈ $570.31 Million |
-0.63pp |
| 2020-12-31 | 1.22% | ₩10.00 Billion ≈ $6.78 Million |
₩818.93 Billion ≈ $554.97 Million |
-0.66pp |
| 2019-12-31 | 1.89% | ₩14.12 Billion ≈ $9.57 Million |
₩748.67 Billion ≈ $507.36 Million |
+1.49pp |
| 2018-12-31 | 0.40% | ₩2.61 Billion ≈ $1.77 Million |
₩652.62 Billion ≈ $442.27 Million |
+0.38pp |
| 2017-12-31 | 0.02% | ₩113.22 Million ≈ $76.73K |
₩639.35 Billion ≈ $433.28 Million |
-- |
About Handok
HANDOK Inc. operates as a pharmaceutical company. The company provides prescription and OTC drugs; medical devices, such as blood pressure monitors, cholesterol monitoring systems, insulin pumps, self-monitoring system of blood glucose, and blood glucose monitoring system; in vitro diagnostic medical devices; as well as life science products. It also offers healthcare products comprising food sup… Read more